Corvus Pharmaceuticals, Inc. (CRVS) Free cash flow 2016–2025
Corvus Pharmaceuticals, Inc. (CRVS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$33.0MFY2025 · since FY2016: -$30.1M → -$33.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$33.0M | — |
| FY2023 | -$24.0M | +12.2% |
| FY2022 | -$27.3M | +25.7% |
| FY2021 | -$36.7M | -5.4% |
| FY2020 | -$34.9M | +6.7% |
| FY2019 | -$37.3M | +9.7% |
| FY2018 | -$41.3M | +11.0% |
| FY2017 | -$46.5M | -54.6% |
| FY2016 | -$30.1M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice